©2024 Stanford Medicine
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Not Recruiting
Trial ID: NCT00673257
Purpose
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients
with cancer. Collecting and storing samples of blood from patients with cancer to study in
the laboratory may help doctors learn more about how patients respond to treatment with
certain chemotherapy drugs.
Official Title
Pharmacokinetics of Daunomycin in Children
Stanford Investigator(s)
Eligibility
DISEASE CHARACTERISTICS:
- Diagnosis of any malignancy
- Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride
administered as an infusion of any duration for < 24 hours on either a 1- or a 2-day
schedule, including bolus and all short infusion schedules
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- No significant uncontrolled systemic illness
- Large implanted prostheses allowed (should not undergo dual energy x-ray
absorptiometry scan)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Intervention(s):
other: pharmacological study
procedure: dual x-ray absorptimetry
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535